Inmazeb ® (atoltivimab, maftivimab, and odesivimab-ebgn) was the first treatment approved by the U.S. Food and Drug Administration (FDA) for Orthoebolavirus zairense , also known as Zaire ebolavirus ...
The company's BCMAxCD3 bispecific antibody Lynozyfic (linvoseltamab) got its first FDA approval as a fifth-line or later ...
All three dose groups (50 mg, 100 mg and 200 mg) showed impressive monotherapy efficacy, with VGPR+ (very good partial response or better) of ...
Regeneron Pharmaceuticals (NASDAQ:REGN) shares witnessed a notable 19% decline on Friday, May 30, in the wake of the unexpected failure of itepekimab, its chronic obstructive pulmonary disease (COPD) ...
Regeneron Pharmaceuticals, a company that has been analyzing genetic data as part of its drug research for more than a decade, is augmenting its capabilities in a big way with the $256 million ...
Tarrytown-based Regeneron would acquire 23andMe for $256 million under the deal that is pending approval by bankruptcy court and regulators. New York-based biotech giant Regeneron Pharmaceuticals ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback